Jim Adox is the Executive Managing Director of Venture Investors Health Fund and is located in Ann Arbor, Michigan. He joined Venture Investors in 2006 as a Managing Director and has 25 years of venture capital experience.
He leverages his technical, operational and venture capital background by focusing on investment prospects in medical devices, diagnostics, and digital health. Jim holds two issued US patents in medical devices.
Jim serves as Chairman of the Board of Directors of HistoSonics, a company Venture Investors spun out of the University of Michigan and in which VIESF IV led the $15 million Series A financing. In addition, Jim serves on the Board of Directors of ViaLase, where he led the Seed and Series A rounds, and Dvant Pharma. He was previously Chairman of the Board of Directors of Tissue Regeneration Systems (TRS), where he was a co-Founder and the Company’s first CEO (acquired by Johnson & Johnson and Medtronic). He also was previously Board Observer of NeuMoDx (acquired by Qiagen for $310 million) and Board Observer of LenSx (acquired by Alcon for up to $744 million).
Prior to his venture capital positions, Jim had nine years operating experience both domestically and internationally. Jim worked in Mexico, Brazil, Argentina and the Czech Republic. In these roles, he wore many functional hats: marketing, engineering, business development and operations. Jim is fluent in Spanish.
Jim is a competitive triathlete, and a five-time Ironman finisher. He is a cyclocross and mountain bike rider and racer, and a 10-time Iceman finisher. In his free time, he enjoys adventures with his family and photography.